SARS-CoV-2 Spike Protein Detected in Brain Arteries of 43.8 Percent of Vaccinated Individuals Even 17 Months After mRNA Vaccination!

Medical News: In what may be one of the most concerning findings to emerge from post-vaccination safety research, Japanese scientists have discovered the lingering presence of SARS-CoV-2 spike proteins in the brain arteries of nearly half of vaccinated individuals - even up to 17 months after receiving their last dose of an mRNA vaccine. The discovery, made during the examination of patients suffering from hemorrhagic strokes, has sparked urgent calls for more research into the long-term biodistribution and biological activity of spike proteins produced by COVID-19 vaccines.


SARS-CoV-2 Spike Protein Detected in Brain Arteries of 43.8 Percent of Vaccinated Individuals
Even 17 Months After mRNA Vaccination

Conducted by researchers from Sapporo Teishinkai Hospital, The Jikei University School of Medicine in Tokyo, Kyoto University School of Medicine, and the National Center for Global Health and Medicine Hospital in Tokyo, the study involved detailed tissue analysis from 19 individuals who had experienced hemorrhagic strokes between March 2023 and April 2024. This Medical News report delves into the implications of their findings, which challenge current assumptions about the behavior of mRNA vaccines long after administration.
 
Alarming Persistence of Spike Protein in Brain Arteries
Using sophisticated immunohistochemical staining methods, the researchers found that in 43.8 percent of vaccinated stroke patients, the SARS-CoV-2 spike protein was still present within the inner layers (intima) of cerebral arteries - up to 17 months post-vaccination. Importantly, none of these patients tested positive for the viral nucleocapsid protein, a marker that would typically suggest active or recent COVID-19 infection. This suggests that the detected spike proteins were not from a natural infection but instead derived from the mRNA vaccines themselves.
 
Equally striking, in situ hybridization techniques confirmed the presence of vaccine-derived mRNA in the brain tissues of select individuals, further validating the spike protein’s vaccine origin. This supports growing concern over the possibility that lipid nanoparticle-encapsulated mRNA could remain active or persist far longer than previously believed.
 
Case Highlights and Surprising Gender Disparities
One remarkable case involved a 70-year-old woman who had received three doses of an mRNA vaccine. Seventeen months after her last dose, she suffered a subarachnoid hemorrhage. Tissue from her cerebral arteries showed spike protein expression despite no history of COVID-19. Similar findings were replicated in other female patients, but notably, no male patient in the study tested positive for spike protein in their brain arteries - a statistically significant gender difference.
 
Among the 16 vaccinated individuals studied, seven showed clear spike protein presence. Intriguingly, among the three unvaccinated patients, two also tested positive for spike protein, raising the possibility of prior undetected asymptomatic infections. However, nuc leocapsid protein remained undetected in all cases, and the two spike-positive unvaccinated patients did not have confirmed COVID-19 diagnoses.
 
This curious concentration of spike protein expression in females suggests that biological sex may influence how the body metabolizes or clears spike protein. Prior research has already shown that women tend to mount more robust immune responses to infections and vaccines, but they are also more likely to develop autoimmune or inflammatory responses. This could help explain why the vaccine-induced spike protein persisted disproportionately in women.
 
Inflammatory Changes Without Full-Blown Vasculitis
Although the study found no signs of active vasculitis (inflammation of blood vessels), mild infiltration by immune cells such as CD4+ and CD8+ T-cells and CD68+ macrophages was observed around spike-positive vessels. These findings hint at subtle but potentially significant immune activity occurring long after vaccination, possibly setting the stage for vascular damage or neurological complications.
 
In patients who tested negative for spike protein, such immune cell infiltration was absent - suggesting a clear immunological response correlated with the presence of spike protein.
 
mRNA Vaccine Behavior May Defy Expectations
The long-lasting presence of vaccine-derived mRNA and spike proteins in brain tissue calls into question the assumption that such components degrade rapidly after vaccination. Earlier studies suggested that mRNA vaccines are cleared from the body within days or weeks, but this research challenges that notion.

Lipid nanoparticles - the delivery vehicles for the mRNA - are known to cross biological barriers such as the blood-brain barrier and the placental barrier. This means they can reach highly sensitive tissues and organs where prolonged protein expression might have unforeseen consequences. Previous reports have documented cases of myocarditis, encephalitis, and other inflammatory responses potentially linked to post-vaccination spike protein activity.
 
The fact that spike protein production could be observed in cerebral arteries more than a year after mRNA vaccination suggests that the actual in vivo behavior of these vaccines is not fully understood and may vary considerably between individuals.
 
Stroke Risk - Coincidence or Consequence?
Although the study does not definitively link spike protein expression to hemorrhagic stroke, the authors caution that the presence of immune activity near brain blood vessels raises red flags. The possibility that the spike protein could disrupt the integrity of blood vessel walls or trigger immune-mediated vascular changes cannot be ruled out.
 
Several mechanisms have been proposed in the literature for how SARS-CoV-2 - or its spike protein - can damage blood vessels, including binding to ACE2 receptors, disrupting blood pressure regulation, inducing hypercoagulability, and triggering endothelial inflammation.
 
Given that hemorrhagic stroke was not observed during initial clinical trials of mRNA vaccines but has since been reported in case studies and population data, the findings underscore the need for more comprehensive long-term safety studies.
 
Need for Replication and Cautious Interpretation
While the study’s findings are undoubtedly concerning, the researchers themselves acknowledge certain limitations. With only 19 patients, the sample size is relatively small. Additionally, even the most advanced detection techniques cannot completely rule out the possibility of prior undiagnosed SARS-CoV-2 infections, especially in asymptomatic cases.
 
Nonetheless, the consistently negative nucleocapsid protein results across all patients bolster the theory that the spike protein detected in this study is primarily vaccine-derived.
 
To avoid premature conclusions, the authors call for urgent global replication studies involving larger patient populations, longer follow-up durations, and even more refined molecular diagnostics. Understanding whether these findings represent isolated anomalies or broader trends is essential for public health decision-making.
 
Final Thoughts and Urgent Questions
This study adds to a growing body of evidence suggesting that the spike protein generated by mRNA vaccines can persist longer and distribute more widely in the body than initially thought. The implications are profound - not only for understanding rare adverse events but also for reevaluating the long-term safety of novel vaccine platforms based on lipid nanoparticle delivery.
 
While mRNA vaccines have been claimed for playing a crucial role in reducing COVID-19 morbidity and mortality (Despite lack of real concrete proof!), their long-term biodistribution and immune effects require more scrutiny. The scientific community must balance the benefits of rapid vaccine deployment with the ethical obligation to investigate and report potential long-term complications.

Until broader studies validate these findings, caution is warranted - especially when considering repeat or booster mRNA vaccinations in populations that may be more vulnerable to spike protein accumulation or immune-mediated vascular responses.
 
The study findings were published in the peer reviewed Journal of Clinical Neuroscience.
https://www.sciencedirect.com/science/article/pii/S096758682500195X
 
For the latest Vaccine News, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/hungarian-researchers-warn-that-covid-19-mrna-vaccines-are-causing-serious-kidney-damage-and-glomerular-issues
 
https://www.thailandmedical.news/news/why-did-fauci-and-the-u-s-nih-stop-supporting-any-studies-on-how-sars-cov-2-or-the-vaccines-affect-the-thymus-in-2021
 
https://www.thailandmedical.news/news/breaking-covid-19-news-doctors-in-thailand-warn-that-covid-19-vaccines-could-possibly-lead-to-tumor-expansion-in-certain-cancers
 
https://www.thailandmedical.news/articles/vaccine-news
 
https://www.thailandmedical.news/pages/thailand_doctors_listings